当前位置:首页 > 文献互助 > 互助详情

Late Breaking Abstract-A Dose-Ranging Study of the Inhaled Dual PDE3/4 Inhibitor TQC3721 in COPD Patients复制

用户JvG4NpPV2vf0 3小时前 25 10 已关闭

DOI:复制

文献链接:复制

其他信息:

Z Luo, L Yang, A Yang, W Li, D Yu, W Li
2024
publications.ersnet.org
Background: TQC3721 is a novel dual phosphodiesterase (PDE) 3 and PDE4 inhibitor with balanced bronchodilator and anti-inflammatory effects, developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Objectives: The objective of this phase IIa clinical trial is to assess the safety and efficacy of TQC3721 in patients with COPD who are on a stable washing-out background therapy. Methods: A randomized, double-blind, placebo-controlled, multiple-ascending-dose study was conducted. Patients with moderate …

互助时间线

2025-10-16 12:59:23 [关闭求助]

楼主用户JvG4NpPV2vf0关闭了求助

2025-10-16 10:10:38 [发起求助]